69-74-9 Usage
Uses
1. Used in Antiviral Applications:
1-beta-D-Arabinofuranosylcytosine hydrochloride is used as an antiviral agent for interfering with the synthesis of DNA, thereby inhibiting the replication of certain viruses.
2. Used in Anticancer Applications:
In the field of oncology, 1-beta-D-Arabinofuranosylcytosine hydrochloride is used as a chemotherapy agent for the treatment of white blood cell cancers such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It works by inhibiting DNA synthesis, which helps to stop the growth and spread of cancer cells.
3. Used in Pharmaceutical Industry:
1-beta-D-Arabinofuranosylcytosine hydrochloride is used as an active pharmaceutical ingredient in the development of drugs for the treatment of various types of cancer and viral infections.
4. Used in Research and Development:
1-beta-D-Arabinofuranosylcytosine hydrochloride is also utilized in research and development for studying the mechanisms of DNA synthesis inhibition and its potential applications in the treatment of other diseases and conditions.
Therapeutic Function
Cancer chemotherapy
Air & Water Reactions
Water soluble. Hydrolysis occurs readily, especially with acid.
Reactivity Profile
1-beta-D-Arabinofuranosylcytosine hydrochloride undergoes decomposition in acidic solutions.
Fire Hazard
Flash point data for 1-beta-D-Arabinofuranosylcytosine hydrochloride are not available; however, 1-beta-D-Arabinofuranosylcytosine hydrochloride is probably combustible.
Biological Activity
cytarabine hydrochloride is an effective drug in the treatment of cancers of white blood cells [1].cytarabine hydrochloride is a dxoxycytidine (dc) analogue. cytarabine hydrochloride has been found to be phosphorylated into a triphophate form, and thus compete with dctp for incorporation into dna. cytarabine hydrochloride has reported to incorporate into dna and block dna synthesis by inhibiting the function of dna and rna polymerases. in addition, incorporated has shown a growth inhibition dose-dependent curve using acute myelogenous leukemia (aml) in a growth inhibition assay with ic50 values of 16nm,103μm and 223μm for ccrf-cem, cem/arac8c and cem/dck-cell lines, respectively. moreover, cytarabine hydrochloride has been exhibited to retrovirally transducer rat leukemic ka cells by wst-1 assay with ic50 values of 0.69μm,1.73μm and 0.037μm for ka, ka/gfp and ka/wt, respectively [1,2].
Biochem/physiol Actions
Ara-C is phosphorylated to Ara-CTP and is incorporatee into DNA. It inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation, and ultimately induces apoptosis via the PKC signaling pathway. Does not inhibit RNA synthesis. Anti-leukemia agent.
Safety Profile
Poison by intravenous route.Moderately toxic by intraperitoneal and subcutaneousroutes. Experimental reproductive effects. A human eyeirritant. Mutation data reported. When heated todecomposition it emits very toxic fumes of NOx and HCl.
references
[1] tobias sc1, borch rf.synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. mol pharm. 2004 mar-apr; 1(2):112-6.[2] veuger mj1, heemskerk mh, honders mw, willemze r, barge rm.functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. blood. 2002 feb 15; 99(4):1373-80.
Check Digit Verification of cas no
The CAS Registry Mumber 69-74-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 69-74:
(4*6)+(3*9)+(2*7)+(1*4)=69
69 % 10 = 9
So 69-74-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H
69-74-9Relevant articles and documents
Preparation method of cytarabine hydrochloride
-
Paragraph 0058-0061; 0070-0073; 0079-0082; 0088-0091, (2019/03/28)
The invention provides a preparation method of cytarabine hydrochloride. The preparation method comprises following steps: A, cytidine and acetylsalicyl chloride are reacted so as to obtain acetyl cyclocytidine; B, acetyl cyclocytidine is subjected to deprotection in a hydrochloric acid methanol solution so as to obtain cyclocytidine hydrochloride; and C, cyclocytidine hydrochloride is subjected to ring-opening reaction so as to obtain cytarabine hydrochloride. The preparation method of cytarabine hydrochloride possesses following advantages: the raw materials are cheap and easily available; using of high toxicity substances difficult to remove is avoided; the preparation method is safe, and is friendly to the environment; and product yield and purity are high.
PROTEIN BINDING COMPOUNDS
-
Page/Page column 20-21, (2010/02/11)
The present invention provides a prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a blood protein binding moiety.
Novel cytarabine monophosphate prodrugs
-
Page/Page column 22, (2008/06/13)
Compounds of Formula I, their preparation and uses are described: wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
-
, (2008/06/13)
A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.
